PT2687532T - Novo derivado de octa-hidrotienoquinolina, composição farmacêutica compreendendo o derivado, e utilização dos mesmos - Google Patents

Novo derivado de octa-hidrotienoquinolina, composição farmacêutica compreendendo o derivado, e utilização dos mesmos

Info

Publication number
PT2687532T
PT2687532T PT127583284T PT12758328T PT2687532T PT 2687532 T PT2687532 T PT 2687532T PT 127583284 T PT127583284 T PT 127583284T PT 12758328 T PT12758328 T PT 12758328T PT 2687532 T PT2687532 T PT 2687532T
Authority
PT
Portugal
Prior art keywords
derivative
pharmaceutical composition
novel
octahydrothienoquinoline
novel octahydrothienoquinoline
Prior art date
Application number
PT127583284T
Other languages
English (en)
Inventor
Nishimura Toshihiro
Teranishi Hirotaka
Yoshida Masako
Ueno Yasunori
Kasai Kiyoshi
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of PT2687532T publication Critical patent/PT2687532T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT127583284T 2011-03-14 2012-03-12 Novo derivado de octa-hidrotienoquinolina, composição farmacêutica compreendendo o derivado, e utilização dos mesmos PT2687532T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011055154 2011-03-14

Publications (1)

Publication Number Publication Date
PT2687532T true PT2687532T (pt) 2017-03-22

Family

ID=46830720

Family Applications (1)

Application Number Title Priority Date Filing Date
PT127583284T PT2687532T (pt) 2011-03-14 2012-03-12 Novo derivado de octa-hidrotienoquinolina, composição farmacêutica compreendendo o derivado, e utilização dos mesmos

Country Status (22)

Country Link
US (1) US9138434B2 (pt)
EP (1) EP2687532B1 (pt)
JP (1) JP5563716B2 (pt)
KR (1) KR101618624B1 (pt)
CN (2) CN104829628B (pt)
AU (1) AU2012227428B2 (pt)
BR (1) BR112013023575B1 (pt)
CA (1) CA2827629C (pt)
DK (1) DK2687532T3 (pt)
ES (1) ES2613658T3 (pt)
HU (1) HUE033449T2 (pt)
IL (1) IL228318A (pt)
MX (1) MX343077B (pt)
MY (1) MY183288A (pt)
PH (1) PH12013501856A1 (pt)
PL (1) PL2687532T3 (pt)
PT (1) PT2687532T (pt)
RU (1) RU2573399C2 (pt)
SG (1) SG193400A1 (pt)
TW (1) TWI537274B (pt)
WO (1) WO2012124649A1 (pt)
ZA (1) ZA201306905B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6166990B2 (ja) * 2012-09-12 2017-07-19 キッセイ薬品工業株式会社 オクタヒドロチエノキノリン誘導体の製造方法及びその製造中間体
US9585885B2 (en) 2012-12-10 2017-03-07 Kissei Pharmaceutical Co., Ltd. Substituted pyrido[2,3-g]quinazolines as dopamine D2 receptor agonists
WO2014112492A1 (ja) * 2013-01-17 2014-07-24 キッセイ薬品工業株式会社 新規なオクタヒドロキノリン誘導体、それを含有する医薬組成物およびそれらの用途
KR102169337B1 (ko) 2018-08-22 2020-10-23 주식회사 도원엔바이로 질소와 인의 흡착형 세라믹 미생물 담체 및 이의 제조방법
US20230286998A1 (en) * 2020-07-06 2023-09-14 Kissei Pharmaceutical Co., Ltd. Succinate salts of octahydrothienoquinoline compound and crystals thereof
JP7773687B2 (ja) * 2020-10-07 2025-11-20 キッセイ薬品工業株式会社 オクタヒドロチエノキノリン化合物の製造方法及びその製造中間体
WO2025143100A1 (ja) 2023-12-28 2025-07-03 キッセイ薬品工業株式会社 神経変性疾患治療剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH507249A (de) 1968-05-31 1971-05-15 Sandoz Ag Verfahren zur Herstellung von 2-Brom-a-ergokryptin
BG17786A3 (bg) 1970-08-14 1973-12-25 Dr. Karl Thomae Gmbh Метод за получаване на нови производни на азепина
US4166182A (en) 1978-02-08 1979-08-28 Eli Lilly And Company 6-n-propyl-8-methoxymethyl or methylmercaptomethylergolines and related compounds
CA1131227A (en) * 1979-01-22 1982-09-07 Nicholas J. Bach Octahydro-2h-pyrrolo (3,4,-g) quinolines
US4526892A (en) * 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
US4452808A (en) 1982-12-07 1984-06-05 Smithkline Beckman Corporation 4-Aminoalkyl-2(3H)-indolones
US4501890A (en) * 1983-09-26 1985-02-26 Eli Lilly And Company Trans-(±)-2,4,6-substituted-5,5a,6,7,8,9,9a,10-octahydro-pyrimido[4,5-g]quinolines
US4537893A (en) 1984-04-27 1985-08-27 Eli Lilly And Company Octahydrothiazolo[4,5-g]quinolines and use as prolactin secretion inhibitors
DE3572485D1 (en) 1984-12-22 1989-09-28 Thomae Gmbh Dr K Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
US4826986A (en) * 1986-06-16 1989-05-02 Eli Lilly And Company 6-Oxo-trans-octa- and decahydroquinolines
US5057515A (en) * 1989-07-24 1991-10-15 Eli Lilly And Company Method for agonizing a dopamine receptor
US7026484B2 (en) * 2001-02-23 2006-04-11 Ligand Pharmaceuticals Incorporated Tricyclic androgen receptor modulator compounds and methods
JP2005129430A (ja) 2003-10-27 2005-05-19 Konica Minolta Holdings Inc 光電変換材料用半導体、光電変換素子及び太陽電池

Also Published As

Publication number Publication date
ZA201306905B (en) 2014-12-23
MX2013010587A (es) 2013-10-07
AU2012227428A1 (en) 2013-09-26
IL228318A0 (en) 2013-11-25
DK2687532T3 (en) 2017-02-20
SG193400A1 (en) 2013-10-30
TW201242970A (en) 2012-11-01
CN104829628B (zh) 2018-01-09
US9138434B2 (en) 2015-09-22
HUE033449T2 (en) 2017-11-28
CN103443106B (zh) 2015-09-30
RU2013145799A (ru) 2015-04-20
US20140243311A1 (en) 2014-08-28
KR101618624B1 (ko) 2016-05-09
PH12013501856A1 (en) 2013-10-14
IL228318A (en) 2017-07-31
AU2012227428B2 (en) 2016-05-05
RU2573399C2 (ru) 2016-01-20
HK1188791A1 (zh) 2014-05-16
MY183288A (en) 2021-02-18
JPWO2012124649A1 (ja) 2014-07-24
BR112013023575B1 (pt) 2021-12-21
CN104829628A (zh) 2015-08-12
ES2613658T3 (es) 2017-05-25
BR112013023575A2 (pt) 2016-12-06
EP2687532A1 (en) 2014-01-22
CN103443106A (zh) 2013-12-11
WO2012124649A1 (ja) 2012-09-20
PL2687532T3 (pl) 2017-06-30
NZ615293A (en) 2014-08-29
MX343077B (es) 2016-10-24
CA2827629C (en) 2019-01-08
BR112013023575A8 (pt) 2018-01-16
EP2687532A4 (en) 2014-08-13
TWI537274B (zh) 2016-06-11
KR20140010137A (ko) 2014-01-23
EP2687532B1 (en) 2016-12-14
CA2827629A1 (en) 2012-09-20
JP5563716B2 (ja) 2014-07-30

Similar Documents

Publication Publication Date Title
ZA201401117B (en) Kynurenine-3-monooxygenase inhibitors,pharmaceutical compositions,and methods of use thereof
IL253911A0 (en) Inhibitors of kynurenine-3-monooxygenase, pharmaceutical compositions, and methods of their use
ZA201206223B (en) Certain kynurenine-3-monooxygenase inhibitors,pharmaceutical compositions, and methods of use thereof
IL234884A0 (en) Inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use
IL236024A (en) The history of benzimidazole-proline and its pharmaceutical preparations
IL230705A0 (en) Certain inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use
IL231008A (en) The history of thiazol, their preparation and their pharmaceutical preparations
IL232914A0 (en) New Azetidine histories, pharmaceutical preparations and their uses
PL2706062T3 (pl) Nowa pochodna cefalosporyny i zawierająca ją kompozycja farmaceutyczna
ZA201403431B (en) Pharmaceutical compositions and methods of use of 4-pregenen-11b-21-triol-3,20-dione derivatives
IL232577A0 (en) The history of morpholinylbenzotriazine, their preparation and pharmaceutical preparations containing them
EP2685993A4 (en) PHARMACEUTICAL COMPOSITIONS AND TOPICAL USE THEREOF
EP2924042A4 (en) BIS-BETA-CARBOLINE COMPOUND AND METHOD OF MANUFACTURING, PHARMACEUTICAL COMPOSITION AND USE THEREOF
PL2773348T3 (pl) Kompozycja farmaceutyczna omeprazolu
IL233238A (en) Sulphonylaminopyrrolidinone derivatives, their preparation and therapeutic use
ZA201306905B (en) Novel octahydrothienoquinonline derivative,pharmaceutical composition comprising derivative, and use of these
IL237146A0 (en) Pharmaceutical compound containing Rabamipide
IL228705A (en) Derivatives of Reliable Phenoxy-Ethyl, Pharmaceutical Preparations Containing and Using Them
IL230219B (en) History of dihydropyrazole, their preparation and pharmaceutical preparations containing them
EP2701689A4 (en) PHARMACEUTICAL COMPOSITIONS OF RALTEEGRAVIR, METHODS OF PREPARATION AND USE THEREOF
IL221501A (en) Medicinal product containing miramistine
AU2011900931A0 (en) Pharmaceutical compositions and use thereof
ZA201309537B (en) Pharmaceutical composition comprising fexofedine